MILPITAS, Calif., May 17, 2016 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced that the company will present new preclinical data on the company’s oral peptide drug candidates for inflammatory bowel disease (IBD), PTG-100 and PTG-200, at Digestive Disease Week 2016 (DDW). PTG-200, a first-in-class, IL-23 oral peptide receptor antagonist, will be the subject of an oral presentation, and PTG-100, an alpha-4-beta-7 integrin-specific oral peptide antagonist, will be the subject of a poster presentation.
DDW is being held in San Diego, CA from May 21-24 at the San Diego Convention Center.
Oral Presentation:
- Discovery of Novel and Potent Orally Stable Peptide Antagonists of the Human IL-23 Receptor and Their Pre-Clinical POC in Rat Colitis Model
Session Title: IBD Target Development: Pre Clinical Studies
Session Date and Time: May 24, 2016 from 10:00 AM to 11:30 AM
Presentation Time: 11:15 AM to 11:30 AM
Session Location: 20BC - SDCC
Poster Presentation:
- Establishing the Human Equivalent Dose for PTG-100, an Oral Peptide Antagonist of Integrin alpha-4-beta-7
Session Title: Animal Models: Pre-Clinical Treatment of Intestinal Inflammation
Session Date & Time: May 24, 2016 from 9:30 AM to 4:00 PM
Poster Presentation Time: Noon - 2:00 PM
Session Location: Hall C
About PTG-100 and PTG 200
PTG-100 is an oral, GI-restricted, alpha-4-beta-7 integrin-specific antagonist peptide currently in Phase 1 clinical trial in normal healthy volunteers, and is being developed initially for potential treatment of moderate-to-severe ulcerative colitis (UC). The integrin pathway is considered to be one of the most specific biological mechanisms for IBD.
PTG-200 is a first-in-class oral, GI-restricted, Interleukin 23 receptor (IL-23R) antagonist peptide that is being developed initially for potential treatment of moderate-to-severe CD. PTG-200 is currently in Investigational New Drug (IND) enabling studies.
PTG-100 and PTG-200 are derived from Protagonist’s proprietary peptide technology platform, and they have the potential of offering oral targeted therapy treatment option for IBD. Protagonist believes PTG-100 and PTG-200 have the potential to transform the existing IBD treatment paradigm because of improved convenience and patient compliance, and potentially improved tolerability compared to injectable antibody drugs.
About Protagonist Therapeutics
Protagonist Therapeutics is a U.S.-incorporated clinical development-stage biotechnology company engaged in the discovery and development of orally stable peptides as targeted therapies initially for inflammatory bowel disease (IBD) and other gastrointestinal diseases and disorders. The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides for protein-protein interaction (PPI) targets that have been approached largely by injectable antibodies. Oral peptides may lead to a preferred choice for patients, physicians, and payers by virtue of their better convenience and potentially enhanced safety and efficacy in comparison to other therapeutic options. PTG-100, an oral alpha-4-beta-7 antagonist peptide, is currently in phase 1 clinical studies. PTG-200, an oral Interleukin-23 receptor antagonist peptide, is currently in IND-enabling studies. In addition to PTG-100 and PTG-200, the company has several other assets in different stages of research and pre-clinical development.
Protagonist is headquartered in Milpitas, California USA with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
Logo - http://photos.prnewswire.com/prnh/20130501/MM06086LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-new-data-for-ptg-100-and-ptg-200-at-digestive-disease-week-2016-300269736.html
SOURCE Protagonist Therapeutics, Inc.
